Literature DB >> 15679011

Rehabilitation of COPD patients: which training modality.

E Clini1, S Costi, M Romagnoli, F Florini.   

Abstract

Non pharmacological therapy has been gaining more interest and has been evolving rapidly over the last decade as an essential part of therapy for COPD patients. Pulmonary Rehabilitation (PR), the most important non pharmacological treatment in patients with COPD, has a primary goal: to achieve the highest possible level of individual exercise tolerance, thus reducing the primary and/or secondary health care utilisation. The aim of the present review is to focus the role of exercise training in these patients as well as to address the question on which training methods are the most beneficial. We have therefore undertaken a MEDLINE-based search including the terms: pulmonary rehabilitation, exercise, lung disease/obstructive. Several strategies based on endurance or strength training are nowadays implemented during PR programmes in order to maximise the benefits for each patient. The impaired function of ambulation muscles causing breathlessness as one of the more frequent symptoms in many COPD, suggests that training the lower extremities is the most important goal to achieve during pulmonary rehabilitation of these patients. On the other hand, as muscle strength appears to be an independent contributor to survival and utilisation of health care resources, it seems largely justified also to include this further modality in the PR program of these patients. In conclusion, both modalities are effective and useful for COPD patients. However, whether resistance training should be administered to all COPD and which is the optimal length of strength training still needs to be elucidated.

Entities:  

Mesh:

Year:  2004        PMID: 15679011     DOI: 10.4081/monaldi.2004.697

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  2 in total

1.  Exercise performance after standard rehabilitation in COPD patients with lung hyperinflation.

Authors:  Ernesto Crisafulli; Elena Venturelli; Gianluca Biscione; Guido Vagheggini; Andrea Iattoni; Sasha Lucic; Nicolino Ambrosino; Franco Pasqua; Alfredo Cesario; Enrico Maria Clini
Journal:  Intern Emerg Med       Date:  2011-11-22       Impact factor: 3.397

2.  Atorvastatin and Simvastatin Promoted Mouse Lung Repair After Cigarette Smoke-Induced Emphysema.

Authors:  Vanessa Pinho-Ribeiro; Adriana Correa Melo; Emanuel Kennedy-Feitosa; Adriane Graca-Reis; Marina Valente Barroso; Isabella Cattani-Cavalieri; Giovanna Marcella Cavalcante Carvalho; Walter Araújo Zin; Luis Cristóvão Porto; Lycia Brito Gitirana; Manuella Lanzetti; Samuel Santos Valença
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.